STOCK TITAN

10x Genomics, Inc. - TXG STOCK NEWS

Welcome to our dedicated page for 10x Genomics news (Ticker: TXG), a resource for investors and traders seeking the latest updates and insights on 10x Genomics stock.

10x Genomics, Inc. (Nasdaq: TXG) is a leading life science technology company based in Pleasanton, California. The company specializes in creating innovative solutions for single cell and spatial biology research, providing researchers with the tools necessary to advance human health by deepening the understanding of complex biological systems.

10x Genomics' product portfolio includes cutting-edge instruments, consumables, and software designed for high-resolution, large-scale analysis of biological systems. Among its notable products are the Chromium Controller, Reagent Kits, 10x Compatible Products, and Informatics Software. The bulk of the company's revenue is generated from the sale of consumables, which are crucial for ongoing research and experimental workflows.

Recently, 10x Genomics launched the GEM-X technology, a significant upgrade to its existing single cell technology. The GEM-X platform offers enhanced performance and reliability, enabling more comprehensive single cell analysis. The company has also introduced the Xenium product line, including the Xenium multi-modal cell segmentation kit and an immuno-oncology gene panel, which expands their single cell spatial analysis capabilities.

Financially, 10x Genomics has demonstrated growth, with 2023 revenue reaching $618.7 million, an increase from the previous year. Although the company reported a net loss for the same period, the launch of new products like the Visium HD Spatial Gene Expression assay and the continued development of the GEM-X technology are expected to drive future growth and adoption among researchers worldwide.

10x Genomics collaborates closely with academic and translational researchers, as well as biopharmaceutical companies, to fuel discoveries in fields such as oncology, immunology, and neuroscience. Their integrated solutions enable scientists to study biological systems at a resolution and scale that aligns with the complexity of biology, making significant contributions to the understanding of health and disease.

To stay up-to-date with 10x Genomics' latest developments, visit their official website at 10xgenomics.com, or follow them on LinkedIn and X (Twitter).

Rhea-AI Summary
10x Genomics to report Q3 2023 financial results
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.98%
Tags
conferences earnings
-
Rhea-AI Summary
UPC denies second preliminary injunction request against NanoString Technologies, Inc.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.81%
Tags
none
-
Rhea-AI Summary
European Unified Patent Court issues preliminary injunction against NanoString for infringing EP 782 patent, preventing sales in 17 countries of the UPC. 10x Genomics intends to seek more than $30 million in damages for sales prior to trial in the US case. Trial for second US suit against NanoString scheduled for September 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.69%
Tags
none
Rhea-AI Summary
10x Genomics announces new kit to expand capabilities of its Chromium Single Cell Gene Expression Flex assay for multiomic cellular profiling
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.48%
Tags
none
-
Rhea-AI Summary
10x Genomics' technologies were used in a study that explains why immune checkpoint blockade is more effective for treating cancers that spread to the brain than for cancers that originate in the brain. The study analyzed resected glioblastoma and brain metastases from patients and found that brain metastases had higher T-cell infiltration into the tumor parenchyma. Researchers also identified an immune subpopulation correlated with better overall survival. The study suggests new combination immunotherapy strategies using blocking inhibitory receptors.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.9%
Tags
none
-
Rhea-AI Summary
10x Genomics, Inc. will participate in a fireside chat at the Morgan Stanley 21st Annual Global Healthcare Conference on September 12. The webcast of the chat will be available on the company's website for replay.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.58%
Tags
conferences
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.19%
Tags
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.83%
Tags
conferences earnings
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.73%
Tags
none
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.41%
Tags
none

FAQ

What is the current stock price of 10x Genomics (TXG)?

The current stock price of 10x Genomics (TXG) is $14.04 as of December 20, 2024.

What is the market cap of 10x Genomics (TXG)?

The market cap of 10x Genomics (TXG) is approximately 1.7B.

What does 10x Genomics, Inc. specialize in?

10x Genomics specializes in creating innovative solutions for single cell and spatial biology research, providing tools for high-resolution, large-scale analysis of biological systems.

What are some of the key products of 10x Genomics?

Key products include the Chromium Controller, Reagent Kits, 10x Compatible Products, Informatics Software, and the recently launched GEM-X and Xenium platforms.

What recent technological advancements has 10x Genomics introduced?

10x Genomics recently launched the GEM-X technology, a significant upgrade for single cell analysis, and the Visium HD Spatial Gene Expression assay for high-resolution spatial discovery research.

How has 10x Genomics performed financially in recent years?

In 2023, 10x Genomics reported a revenue of $618.7 million, reflecting a year-over-year increase. The company's continued innovation and product development are expected to drive future growth.

Who are the primary users of 10x Genomics' products?

10x Genomics' products are used by academic and translational researchers as well as biopharmaceutical companies to advance research in fields such as oncology, immunology, and neuroscience.

What is the significance of GEM-X technology?

GEM-X technology offers improved performance and reliability for single cell analysis, enabling more comprehensive research and better understanding of biological complexities.

Where can I find the latest news about 10x Genomics?

For the latest news and updates, visit 10x Genomics' official website at https://www.10xgenomics.com or follow them on LinkedIn and X (Twitter).

What is the focus of 10x Genomics' recent product launches?

Recent product launches focus on enhancing single cell and spatial biology research capabilities, including new assays and technology platforms like GEM-X and Visium HD.

What is the impact of 10x Genomics' products on scientific research?

10x Genomics' products enable high-resolution, large-scale analysis of biological systems, driving breakthroughs and transforming our understanding of health and disease.

How does 10x Genomics contribute to the field of biology?

10x Genomics provides tools that allow researchers to study biological systems at a resolution and scale that matches their complexity, facilitating significant scientific discoveries.

10x Genomics, Inc.

Nasdaq:TXG

TXG Rankings

TXG Stock Data

1.69B
103.99M
2.15%
96.03%
5.67%
Health Information Services
Laboratory Analytical Instruments
Link
United States of America
PLEASANTON